Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.
Aimee Keegan, PharmD, BCOP
Advertisement
Articles by Aimee Keegan, PharmD, BCOP
A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.
Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.
Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.
Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.
Advertisement
Latest Updated Articles
NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast CancerPublished: April 24th 2024 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
2
Meeting Patients Where They Are: How Pharmacists Are Helping People Stay on Track With Schizophrenia Treatment
3
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
4
Incidence of Invasive Fungal Infections Following BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma
5
